Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Non-radiographic axial spondyloarthritis; Spondylarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 20 Dec 2021 This trial has been Completed in Hungary, according to European Clinical Trials Database record.
- 18 Sep 2018 Results assessing safety and efficacy from 3 studies (NCT02437162, NCT02438787 and NCT02407223) published in the Arthritis and Rheumatology
- 23 Oct 2017 Status changed from active, no longer recruiting to discontinued because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.